Pharis Biotec

Pharis Biotec is a German biotechnology company specializing in the discovery and development of therapeutic peptides derived from human biological fluids. The company utilizes its proprietary Peptide Bank, a comprehensive collection of naturally occurring peptides, to identify candidates for treating cardiovascular, renal, and inflammatory diseases. Its lead program, Ularitide, is a synthetic form of the human natriuretic peptide urodilatin and has been evaluated in Phase 3 clinical trials for acute heart failure. Pharis Biotec primarily operates as a research and intellectual property entity, licensing its discoveries to clinical-stage partners for further development.